{
    "clinical_study": {
        "@rank": "138023", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "20 patients will be treated with the first planned dose, i.e. 20 \u00b5g/mL"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "After completion of Group 1 treatment, data on primary efficacy and safety variables will be reviewed to identify the appropriate dose for Group 2"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to assess the efficacy and safety of different doses of rhNGF\n      when administered as eye drops to patients with Dry Eye."
        }, 
        "brief_title": "Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye", 
        "condition": "Dry Eye Syndrome.", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patients, \u2265 18 years old;\n\n          2. Required use of artificial tears for the treatment of Dry Eye within the 3 months\n             prior to study enrolment;\n\n          3. Current use or recommended use of artificial tears for the treatment of Dry Eye;\n\n          4. Average VAS score for typical symptoms of Dry Eye (foreign body sensation,\n             burning/stinging, itching, pain, stick feeling, blurred vision and photophobia) \u2265 25\n             mm;\n\n          5. Corneal staining score with lissamine green > 3 using the NEI corneal grading system\n             in the worse eye (study eye);\n\n          6. Conjunctival staining score > 3 using the NEI conjunctival grading system in the\n             worse eye (study eye);\n\n          7. Schirmer test without anaesthesia \u2264 10 mm/5 minutes in the worse eye (study eye);\n\n          8. Tear film break-up time (TBUT) \u2264 10 seconds in the worse eye (study eye);\n\n          9. A negative urine pregnancy test if female of childbearing potential and must use\n             adequate birth control throughout the study period\n\n        Exclusion Criteria:\n\n          1. Patient not suitable to participate in the study in the opinion of the investigator;\n\n          2. Patient with a mild or moderate Dry Eye condition (severity level less than 3\n             according to the Report of the International Dry Eye Workshop -DEWS, 2007) if\n             fourteen (14) patients with mild or moderate dry eye condition have been already\n             enrolled in the current treatment group (Group 1 and Group 2 separately);\n\n          3. Patient has had a serious adverse reaction or significant hypersensitivity to any\n             drug or chemically related compounds or has a clinically significant allergy to\n             drugs, foods, amide local anaesthetics or other materials including commercial\n             artificial tears containing Hypromellose (in the opinion of the investigator);\n\n          4. Use of topical cyclosporine, topical corticosteroids or any other topical medication\n             for the treatment of dry eye in either eye within 30 days of study enrolment. Use of\n             own artificial tears is allowed until Visit 2;\n\n          5. Any ocular disease other than Dry Eye requiring treatment with topical medications in\n             either eye within 30 days of study enrolment;\n\n          6. Any active ocular infection or active inflammation in either eye unrelated to Dry\n             Eye;\n\n          7. Presence or history of any systemic or ocular disorder, condition or disease that\n             could possibly interfere with the conduct of the required study procedures or the\n             interpretation of the study results;\n\n          8. Use of therapeutic or Refractive Contact lenses in either eye within 30 days of study\n             enrolment;\n\n          9. History of ocular surgery in the study eye, including corneal refractive procedures,\n             within 90 days of study enrolment;\n\n         10. Participation in another clinical study at the same time as the present and within 30\n             days of study enrolment;\n\n         11. History of drug, medication or alcohol abuse or addiction."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101281", 
            "org_study_id": "NGF0213", 
            "secondary_id": "2013-004271-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "1 drop  for each eye, twice daily for 28 day", 
                "intervention_name": "Human nerve growth factor 20 \u00b5g/mL", 
                "intervention_type": "Biological", 
                "other_name": "rhNGF"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "either 4 \u00b5g/mL, option 1 or 60 \u00b5g/mL, option 2; 1 drop  each eye, twice daily for 28 day", 
                "intervention_name": "Human nerve growth factor 4 \u00b5g/mL or 60 \u00b5g/mL", 
                "intervention_type": "Biological", 
                "other_name": "rhNGF"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mitogens"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Dry Eye", 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "contact": {
                "email": "gerhard.garhoefer@meduniwien.ac.at", 
                "last_name": "Gerhard Garh\u00f6fer, MD", 
                "phone": "+43 1 40400", 
                "phone_ext": "2980"
            }, 
            "contact_backup": {
                "email": "doreen.schmidl@meduniwien.ac.at", 
                "last_name": "Doreen Schmidl, MD", 
                "phone": "+43 1 40400", 
                "phone_ext": "2980"
            }, 
            "facility": {
                "address": {
                    "city": "Wien", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Department of Clinical Pharmacology"
            }, 
            "investigator": [
                {
                    "last_name": "Gerhard Garh\u00f6fer, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Doreen Schmidl, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye", 
        "overall_contact": {
            "email": "mauro.ferrari@dompe.it", 
            "last_name": "Mauro P. Ferrari, PharmD", 
            "phone": "+39 02 58383", 
            "phone_ext": "271"
        }, 
        "overall_contact_backup": {
            "email": "francesco.sinigaglia@dompe.it", 
            "last_name": "Francesco Sinigaglia, MD", 
            "phone": "+39 02 58383", 
            "phone_ext": "275"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Vienna, Vienna General Hospital, AKH", 
            "last_name": "Gerhard Garh\u00f6fer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Symptom Assessment in Dry Eye (SANDE)", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day  56\u00b14"
            }, 
            {
                "measure": "Ocular surface vital staining", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Schirmer test type I", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Treatment-emergent adverse events (TEAEs),", 
                "safety_issue": "Yes", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Visual analogue scale (VAS)", 
                "safety_issue": "Yes", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Slit lamp examination", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Schirmer test type II (with anaesthesia)", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Tear Film Break-Up Time (TFBUT)", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Corneal fluorescein staining", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Corneal sensitivity (Cochet-Bonnet aesthesiometry)", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Intraocular Pressure (IOP)", 
                "safety_issue": "Yes", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Ocular Surface Disease Index (OSDI)", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Visual acuity", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Fundus ophthalmoscopy", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Tear Film osmolarity", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Conjunctival impression cytology for goblet cells' count Tear Film osmolarity", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline up to day 56\u00b14"
            }, 
            {
                "measure": "Frequency of artificial tears use", 
                "safety_issue": "No", 
                "time_frame": "Changes from day 1 to 56\u00b14"
            }
        ], 
        "source": "Domp\u00e9 s.p.a.", 
        "sponsors": {
            "collaborator": {
                "agency": "CROSS  S.A.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Domp\u00e9 s.p.a.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}